Buckingham Asset Management LLC Boosts Stake in Eli Lilly And Co (LLY)

Buckingham Asset Management LLC grew its position in shares of Eli Lilly And Co (NYSE:LLY) by 19.4% in the first quarter, Holdings Channel reports. The fund owned 4,568 shares of the company’s stock after buying an additional 741 shares during the quarter. Buckingham Asset Management LLC’s holdings in Eli Lilly And Co were worth $593,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc increased its stake in shares of Eli Lilly And Co by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock worth $7,955,211,000 after purchasing an additional 511,752 shares during the last quarter. Legacy Financial Advisors Inc. increased its stake in shares of Eli Lilly And Co by 33.2% during the 4th quarter. Legacy Financial Advisors Inc. now owns 1,562 shares of the company’s stock worth $181,000 after purchasing an additional 389 shares during the last quarter. Cornerstone Advisors Inc. increased its stake in shares of Eli Lilly And Co by 18.2% during the 4th quarter. Cornerstone Advisors Inc. now owns 917 shares of the company’s stock worth $106,000 after purchasing an additional 141 shares during the last quarter. Evanson Asset Management LLC acquired a new position in shares of Eli Lilly And Co during the 4th quarter worth about $268,000. Finally, Pratt Collard Advisory Partners LLC increased its stake in shares of Eli Lilly And Co by 6.0% during the 4th quarter. Pratt Collard Advisory Partners LLC now owns 9,750 shares of the company’s stock worth $1,128,000 after purchasing an additional 550 shares during the last quarter. Hedge funds and other institutional investors own 84.49% of the company’s stock.

Shares of LLY stock opened at $116.01 on Friday. The stock has a market cap of $113.33 billion, a P/E ratio of 20.90, a P/E/G ratio of 2.07 and a beta of 0.27. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50. Eli Lilly And Co has a 52 week low of $81.49 and a 52 week high of $132.13.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, topping the consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. Eli Lilly And Co’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.31 EPS. On average, research analysts forecast that Eli Lilly And Co will post 5.66 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Friday, May 17th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.22%. The ex-dividend date of this dividend is Thursday, May 16th. Eli Lilly And Co’s payout ratio is 46.49%.

LLY has been the topic of several recent analyst reports. Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. UBS Group lowered their price objective on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research note on Friday, February 8th. Bank of America set a $129.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research note on Thursday, March 21st. BMO Capital Markets boosted their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Finally, Citigroup set a $124.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research note on Tuesday, February 26th. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $118.15.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $122.48, for a total value of $25,108,400.00. Following the completion of the sale, the insider now owns 117,641,684 shares of the company’s stock, valued at approximately $14,408,753,456.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The disclosure for this sale can be found here. Insiders have sold a total of 845,959 shares of company stock valued at $106,647,752 in the last ninety days. 0.11% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This news story was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/19/buckingham-asset-management-llc-boosts-stake-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What is the formula for the cash asset ratio?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.